Scientists have found that loss-of-function of the RNA-specific adenosine deaminase ADAR1 in tumour cells enhances immunotherapy sensitivity and overcomes resistance to immune checkpoint blockade [49]. The gene discussed is ADAR; the disease is neoplasm.